Trial Profile
An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TARGET3D
- 22 Feb 2023 Results (n=23) assessing the efficacy of glecaprevir-pibrentasvir for four weeks in people with recent HCV infection, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
- 19 Aug 2022 Status changed from recruiting to completed.
- 23 Jun 2021 Planned End Date changed from 1 Dec 2025 to 1 Dec 2024.